Health and Medicines Notices




NEW ZEALAND GAZETTE, No. 195

18 DECEMBER 2008


Medicines Act 1981

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Product: Children’s Claratyne
Active Ingredient: Loratadine 5mg
Dosage Form: Chewable tablet
New Zealand Sponsor: Schering-Plough a division of Schering-Plough Animal Health Limited
Manufacturers: Schering Corporation (USA), Kenilworth, New Jersey, United States of America

Product: Nurofen Zavance Caplets (General Sale)
Active Ingredient: Ibuprofen sodium dihydrate 256mg equivalent to Ibuprofen 200mg
Dosage Form: Coated tablet
New Zealand Sponsor: Reckitt Benckiser (New Zealand) Limited
Manufacturer: Reckitt Benckiser Healthcare International Limited, Nottingham, Nottinghamshire, United Kingdom

Product: Nurofen Zavance Caplets (Pharmacy Only)
Active Ingredient: Ibuprofen sodium dihydrate 256mg equivalent to Ibuprofen 200mg
Dosage Form: Coated tablet
New Zealand Sponsor: Reckitt Benckiser (New Zealand) Limited
Manufacturer: Reckitt Benckiser Healthcare International Limited, Nottingham, Nottinghamshire, United Kingdom

Product: Nurofen Zavance Tablets (General Sale)
Active Ingredient: Ibuprofen sodium dihydrate 256mg equivalent to Ibuprofen 200mg
Dosage Form: Coated tablet
New Zealand Sponsor: Reckitt Benckiser (New Zealand) Limited
Manufacturer: Reckitt Benckiser Healthcare International Limited, Nottingham, Nottinghamshire, United Kingdom

Product: Nurofen Zavance Tablets (Pharmacy Only)
Active Ingredient: Ibuprofen sodium dihydrate 256mg equivalent to Ibuprofen 200mg
Dosage Form: Coated tablet
New Zealand Sponsor: Reckitt Benckiser (New Zealand) Limited
Manufacturer: Reckitt Benckiser Healthcare International Limited, Nottingham, Nottinghamshire, United Kingdom

Product: Spiriva Respimat
Active Ingredient: Tiotropium bromide monohydrate 3.125μg/dose equivalent to Tiotropium 2.5μg/dose
Dosage Form: Solution for inhalation
New Zealand Sponsor: Boehringer Ingelheim (NZ) Ltd
Manufacturer: Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

Dated this 12th day of December 2008.

MARK RICHARDS, Acting Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).


Mental Health (Compulsory Assessment and Treatment) Act 1992

Mental Health (Compulsory Assessment and Treatment) Act Notice 2008—Appointment of Director of Area Mental Health Services

Pursuant to section 92 of the Mental Health (Compulsory Assessment and Treatment) Act 1992, I, Stephen Bruce McKernan, Director-General of Health, give the following notice.

Notice

  1. This notice shall be read together with the Mental Health (Compulsory Assessment and Treatment) Act Notice

2000—Appointment of Directors of Area Mental Health Services (“the principal notice”)*.

  1. The Schedule to the principal notice is amended in respect of

"Area 7—Waikato"
by adding the name and title

"Dr Rees Tapsell, consultant psychiatrist, of Waikato."

Dated at Wellington this 9th day of December 2008.

STEPHEN BRUCE MCKERNAN, Director-General of Health.

*New Zealand Gazette, 31 August 2000, No. 117, page 2963



Next Page →



Online Sources for this page:

Gazette.govt.nz PDF NZ Gazette 2008, No 195





✨ LLM interpretation of page content

🏥 Consent to Distribution of New Medicines under Medicines Act 1981

🏥 Health & Social Welfare
12 December 2008
Medicines, Distribution, Loratadine, Ibuprofen, Tiotropium
  • MARK RICHARDS, Acting Deputy Director-General, Sector Accountability and Funding Directorate

🏥 Appointment of Director of Area Mental Health Services

🏥 Health & Social Welfare
9 December 2008
Mental Health, Director Appointment, Waikato
  • Rees Tapsell (Dr), Appointed Director of Area Mental Health Services

  • STEPHEN BRUCE MCKERNAN, Director-General of Health